John F. Milligan
 | This article, John F. Milligan, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
John F. Milligan, Ph.D. is the CEO of Gilead Sciences, a biotechnology company based in the United States since March of 2016. He was previously appointed President of the company and has maintained that role since May of 2008.[1] He has held various other positions during his tenure with Gilead which includes COO and CFO and originally joined the biotechnology company back in 1990 as a research scientist.[1] John inherited his current role as CEO when former CEO John C. Martin was appointed to Executive Chairman of the company.[2] John has over 25 years of experience with the company and many lessons learned under the tutelage of Martin.[3]
Education
John received his bachelors degree from Ohio Wesleyan University and doctorate from the University of Illinois-Urbana-Champaign in the field of biochemistry.[1] He also was a postdoctoral fellow for the American Cancer Society at the University of California at San Francisco.[1]
Career
Upon joining Gilead in 1990, John has served multiple roles at the biotechnology company. After starting out as a research scientist, he has taken on leadership positions within the company which included Director of Project Management for the drug collaboration of Tamiflu with Hoffman-La Roche in 1996.[1] In March of 2000, he became Vice President of Corporate Development and was responsible for coordinating licensing agreements between corporate partners as well as mergers and acquisitions to expand Gilead and develop its robust drug pipeline.[1] Additionally, he has been the Director of Pharmasset since January of 2012 and Director of Pacific Biosciences since July of 2013.[1]
Achievements
In 2006 and 2007, Institutional Investor magazine named John top CFO in the biotechnology industry.[1] Also in 2006, he was distinguished as "Bay Area Chief Financial Officer of the Year" which is awarded to leaders of companies whose annual revenues exceed $500 million.[1] Most recently, in 2016, John was named to the Forbes Global Game Changers List which represents exceptional leaders and innovators in various industries.[4]
References
- ^ a b c d e f g h i "Stocks". Bloomberg.com. Retrieved 2017-02-18.
- ^ "Gilead's John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director | Business Wire". www.businesswire.com. Retrieved 2017-02-18.
- ^ "Gilead Chief Has $21 Billion in Cash and an Itch to Do a Deal". Bloomberg.com. 2016-05-06. Retrieved 2017-02-18.
- ^ "Global Game Changers 2016". Forbes. Retrieved 2017-02-18.
Request review of new Wikipedia page for John F. Milligan, CEO of Gilead Sciences.
| This article, John F. Milligan, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |